Business Development Manager

CMP Scientific and Eurofins BPT China Laboratory announce strategic collaboration to deliver advanced CE-MS services for biopharmaceutical characterization. CMP Scientific Corp Feb 11, 2026, 11:15 ET The partnership expands access to state-of-the-art cIEF-MS and CZE-MS workflows, supporting recombinant protein therapeutics across research, development, and regulatory submissions, with direct molecular identification of charge variants and impurities. BROOKLYN, N.Y., Feb. 11, 2026 /PRNewswire-PRWeb/ - CMP Scientific today announced a strategic collaboration with Eurofins BioPharma Product Testing China Laboratory to provide advanced capillary electrophoresis - mass spectrometry (CE-MS) services for comprehensive characterization of biopharmaceutical products to customers worldwide. As part of this collaboration, CMP Scientific has begun providing its proprietary CR3520 online cIEF-MS charge variant analysis workflow to support biopharmaceutical development and BLA submissions for Eurofins' clients. In addition, CMP Scientific will implement its EMASS-II CE-MS technology within Eurofins Laboratories, where it will be integrated with multiple high-resolution mass spectrometry platforms to create an instrument-agnostic CE-MS capability. This approach is designed to maximize the performance and flexibility of each mass spectrometer system while delivering robust, high-quality CE-MS data. "At CMP Scientific, our mission is to empower biopharmaceutical laboratories with world-class CE-MS analytical workflows," said Dr. James Xia, CEO of CMP Scientific. "We're excited to collaborate with Eurofins to make high-performance CE-MS technologies more broadly accessible. By combining CMP's CE-MS expertise with Eurofins' powerful analytical services infrastructure, we enable researchers to gain deeper molecular insights and accelerate biopharmaceutical development." Mr. Ang Zhang, General Manager of Eurofins BPT China, stated: "This collaboration reflects Eurofins' continued commitment to providing cutting-edge analytical solutions for innovative biopharmaceutical and biotechnology companies. Through our partnership with CMP Scientific, we are expanding access to advanced and reliable CE-MS analytical workflows, thereby enhancing our capabilities in characterizing complex biomolecules." The new CE-MS analysis services, including CR3520 online cIEF-MS charge variant analysis and CZE-MS peak identification for CE-SDS impurity analysis, are expected to be available to Eurofins customers starting in March 2026, initially launched at the Eurofins BPT Shanghai laboratory. These services will provide advanced analytical strategies to support recombinant protein therapeutic products during research, development, and regulatory submission phases, enabling a "what you see is what you identify" approach and elevating charge variant and impurity analysis to a whole new level. Traditional cIEF and CE-SDS are "non-mass spectrometry" methods based on migration time or UV detection. While they offer excellent separation, their ability to identify peaks is limited, usually relying on comparison with standards or inference. For example, cIEF separates charge variants based on isoelectric point (pI), but if specific details of the variants (such as deamidation, glycosylation, C-terminal lysine heterogeneity, pyroglutamate cyclization, fragmentation, aggregation, etc.) need to be identified, offline MS analysis of collected fractions is required. This process involves complex fraction collection, desalting, and re-injection, which is not only cumbersome and time-consuming but also prone to errors. The CR3520 online cIEF-MS charge variant analysis can not only separate the main peak and multiple micro-heterogeneity peaks but also immediately obtain precise molecular weight information for each charge variant, thus directly identifying the type of modification causing the charge difference. Furthermore, in forced degradation or stability studies, the CR3520 online cIEF-MS charge variant analysis can observe the trend of specific modifications (such as deamidation) over time and under different conditions, directly correlating them with pI shifts, providing direct evidence for understanding protein degradation pathways. The situation with CE-SDS is similar. Traditional CE-SDS uses SDS and coated capillaries, relying solely on migration time and molecular weight standards for identification, and is not compatible with MS. CMP Scientific has developed an innovative CZE-MS method system. Through improved ion source interfaces and buffer systems (such as using MS-friendly surfactants or avoiding direct entry of SDS into the mass spectrometer), they have successfully achieved the identification and analysis of CE-SDS-related components, representing a significant technological breakthrough. For fragment peaks in non-reducing CE-SDS, it is possible to directly determine whether they are light chain (LC), heavy chain (HC), F(ab')2, or Fc fragments. For reducing CE-SDS, it can identify whether it is the complete light chain, heavy chain, or non-glycosylated heavy chain, etc. This provides irrefutable evidence for impurity tracing (such as enzyme cleavage sites) in process development. This technology can also be used to confirm covalent modifications that cause apparent molecular weight changes. For example, different drug-to-antibody ratio (DAR) species in ADC drugs will exhibit different migration patterns in non-reducing CE-SDS. CZE-MS can directly identify the DAR value corresponding to each peak and correlate it with the UV chromatogram. About CMP Scientific CMP Scientific is a leading innovator in analytical instrumentation, specializing in capillary electrophoresis and CE-MS interfaces that enable advanced biomolecular analysis. The company's proprietary CE-MS technology integrates high-efficiency CE separation with high-resolution mass spectrometry, enabling comprehensive characterization of biopharmaceutical products across both CZE-MS and cIEF-MS workflows. About Eurofins BioPharma Product Testing China Laboratory Eurofins BioPharma Product Testing (EBPT) is the biopharmaceutical testing division of the Eurofins Group, operating one of the world's largest unified GMP biopharmaceutical product testing laboratory networks. EBPT provides comprehensive analytical testing services to pharmaceutical, biopharmaceutical, and medical device companies worldwide. With more than 42 laboratories globally, EBPT delivers consistent, high-quality testing through a harmonized quality system, centralized billing model, and deep global regulatory expertise. EBPT China operates two laboratories in Shanghai, specializing in full-lifecycle analytical testing and method development for large-molecule therapeutics, including proteins, ADCs, vaccines, and cell and gene therapies. The team has extensive experience supporting drug development and regulatory submissions and is widely recognized for its strong industry reputation. Media Contact SOURCE CMP Scientific Corp

Eurofins CDMO Alphora joins international consortium project to advance next generation ADC expression platform. Business Wire In this article: MISSISSAUGA, Ontario, February 05, 2026-(BUSINESS WIRE)-Eurofins CDMO Alphora is pleased to announce that its Canadian-based division is receiving advisory services and funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to support a research and development collaboration project focused on advancing a transformative approach for next-generation ADC (antibody-drug conjugate) production to meet the growing demand for targeted therapeutics. As part of this initiative, Eurofins CDMO Alphora (Canada) is collaborating with Daresbury Proteins Ltd. (UK) to contribute its development and manufacturing expertise to the NextGen ADC Platform: Engineering High Yielding Expression Vectors and Peptide Linker Tags for Advanced ADC Production initiative. This ground breaking project aims to develop a novel, high yield expression platform that integrates optimized affinity peptide tags directly into monoclonal antibody (mAb) production. By engineering these tags into the expression system itself, the platform streamlines antibody - drug conjugate (ADC) manufacturing by eliminating several traditional conjugation and purification steps. The resulting process is designed to reduce ADC manufacturing complexity and cost while accelerating development timelines. Looking ahead, the initiative aims to lay the foundation for future production of clinic-ready ADCs designed for efficient point-of-care reconstitution, with the potential to generate significant benefits across clinical and commercial supply chains. By combining Eurofins CDMO Alphora's proven capabilities in complex drug development and manufacturing with specialized protein expression technology from Daresbury Proteins Ltd., and support from NRC IRAP, the project is positioned to drive forward innovative solutions, foster highly-skilled job creation, and support Canada's capacity to produce the next wave of precision biologics. About Eurofins CDMO Alphora Eurofins CDMO Alphora, part of an international network of Eurofins Scientific, develops and manufactures small molecule & biologic drug substances and drug products "under one roof" in Mississauga, Ontario, Canada. Our small molecule capabilities include the development and manufacture of API's and HPAPI's, oral drug products and API solid-state R&D. Our biologics capabilities include the development and manufacture of mAbs, proteins and ADCs, and Sterile Fill (2026). Established in 2003, our FDA, Health Canada, and Japan PMDA inspected site has over 250 people.

Eurofins announces nearly $150 million expansion to Lancaster County lab. Eurofins Lancaster Laboratories on Monday announced that it will add a new 300,000-square-foot biopharmaceutical testing facility and office to its Leola campus, costing about $147 million and adding about 250 jobs over the next three years. Neal Salerno, senior vice president of Eurofins BioPharma Product Testing, said he's been working with state officials to plan the project for the past year. "From our humble roots as a small food testing lab, Eurofins is now the number one testing organization, ensuring that the air you breathe, the water you drink, the food you eat, the medicine you take and the medical devices that you use are safe," Salerno said during a news conference on Monday. Lancaster Laboratories was founded in 1961 and provides testing services for biopharmaceutical and pharmaceutical products. In 2011, Belgium-based Eurofins purchased the company. A collection of interviews, photos, and music videos, featuring local musicians who have stopped by the WITF performance studio to share a little discussion and sound. Produced by WITF's Joe Ulrich. Salerno did not provide a specific timeline for the project. During the announcement, he was surrounded by state and local officials, as well as Eurofins scientists in white lab coats. Gov. Josh Shapiro was on hand to announce his administration would provide more than $2 million to help fund the project. "We're not only helping bring more crucial testing to more people - we're creating more new opportunities for folks here in Lancaster," the first-term Democrat said. "We know that when we invest in a company like Eurofins, we're also having a positive downstream impact on industries that rely on the testing Eurofins provides." The state dollars going toward the projects, according to state Secretary of Community and Economic Development Rick Siger, are almost entirely - about $1.8 million - from a Pennsylvania First Fund grant. Another $375,000, Siger said, would come from the WEDnetPA grant program and would go toward on-the-job training for new employees. Eurofins' latest planned expansion would mark its largest to date, after a five-story, $42 million space opened in 2019. For that project, the state provided the company about $1 million in grant money and $1 million in tax credits. Ezra Rothman, president of EDC Lancaster, celebrated Eurofins' announcement. He pointed to the company's partnership with local educational institutions, like Millersville University, to say students will have a direct "pipeline" to "highly technical, future-oriented jobs." A political economy. Shapiro heavily stressed the positive economic impact that Eurofins' expansion for Lancaster County and Pennsylvania, broadly. "This is a company that quite literally is the leader in the world," Shapiro said. "And so it means they can be anywhere in the world, but they've chosen to be here in Lancaster." Shapiro is a rumored contender for the Democratic Party's 2028 presidential nomination, and in recent months has increasingly voiced his opposition to President Donald Trump's handling of the economy. Shapiro pointed to several positive economic outlooks for Pennsylvania: Moody's rated it as the only state in the northeast with a growing economy, and Forbes named it one of the best states in the country to start a business. His words at Eurofins come after posting weeks' worth of criticism toward Trump and Vice President JD Vance, who both separately visited Pennsylvania this month to tout the federal administration's economic record. The Bureau of Labor Statistics' report this month found unemployment reached 4.6% in November, from 4% at the beginning of Trump's term in January. And between October and November, the U.S. has lost more than 40,000 net jobs, though November saw jobs added to the economy. Help support the information and news you've come to rely on in central Pennsylvania. with a donation to WITF.